R
45.40
-0.07 (-0.15%)
| Previous Close | 45.47 |
| Open | 45.42 |
| Volume | 2,518,133 |
| Avg. Volume (3M) | 4,061,635 |
| Market Cap | 26,259,779,584 |
| Price / Earnings (TTM) | 25.51 |
| Price / Earnings (Forward) | 14.86 |
| Price / Sales | 11.08 |
| Price / Book | 3.09 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| TTM Dividend Yield | 1.97% |
| Profit Margin | 48.26% |
| Operating Margin (TTM) | 94.00% |
| Diluted EPS (TTM) | 2.45 |
| Quarterly Earnings Growth (YOY) | 4,888.50% |
| Total Debt/Equity (MRQ) | 77.82% |
| Current Ratio (MRQ) | 1.56 |
| Operating Cash Flow (TTM) | 2.70 B |
| Levered Free Cash Flow (TTM) | -1.36 B |
| Return on Assets (TTM) | 7.04% |
| Return on Equity (TTM) | 18.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Royalty Pharma plc | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 1.5 |
| Insider Activity | -1.5 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Value |
| % Held by Insiders | 8.92% |
| % Held by Institutions | 79.64% |
| 52 Weeks Range | ||
| Median | 50.00 (10.13%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 27 Jan 2026 | 50.00 (10.13%) | Buy | 40.74 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COYNE TERRANCE P. | - | 47.47 | -34,791 | -1,651,529 |
| Aggregate Net Quantity | -34,791 | |||
| Aggregate Net Value ($) | -1,651,529 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 47.47 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COYNE TERRANCE P. | Officer | 02 Mar 2026 | Automatic sell (-) | 34,791 | 47.47 | 1,651,529 |
| Date | Type | Details |
|---|---|---|
| 20 Jan 2026 | Announcement | Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 |
| 12 Jan 2026 | Announcement | Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference |
| 11 Jan 2026 | Announcement | Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo |
| 11 Jan 2026 | Announcement | Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo |
| 09 Jan 2026 | Announcement | Royalty Pharma Announces Dividend Increase |
| 29 Dec 2025 | Announcement | Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones |
| 16 Dec 2025 | Announcement | Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million |
| TTM Dividend Yield | 1.97% |
| 5Y Average Dividend Yield | 2.41% |
| Payout Ratio | 34.69% |
| Expected Next Dividend Payment | Jun 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 20 Feb 2026 | 09 Jan 2026 | 10 Mar 2026 | 0.235 Cash |
| 14 Nov 2025 | 17 Oct 2025 | 10 Dec 2025 | 0.22 Cash |
| 15 Aug 2025 | 18 Jul 2025 | 10 Sep 2025 | 0.22 Cash |
| 16 May 2025 | 21 Apr 2025 | 10 Jun 2025 | 0.22 Cash |
| 21 Feb 2025 | 09 Jan 2025 | 10 Mar 2025 | 0.22 Cash |
| 15 Nov 2024 | 11 Oct 2024 | 10 Dec 2024 | 0.21 Cash |
| 16 Aug 2024 | 17 Jul 2024 | 13 Sep 2024 | 0.21 Cash |
| 16 May 2024 | 17 Apr 2024 | 14 Jun 2024 | 0.21 Cash |
| 15 Feb 2024 | 19 Jan 2024 | 15 Mar 2024 | 0.21 Cash |
| 16 Nov 2023 | 16 Oct 2023 | 15 Dec 2023 | 0.2 Cash |
| 17 Aug 2023 | 17 Jul 2023 | 15 Sep 2023 | 0.2 Cash |
| 18 May 2023 | 17 Apr 2023 | 15 Jun 2023 | 0.2 Cash |
| 15 Feb 2023 | 09 Jan 2023 | 15 Mar 2023 | 0.2 Cash |
| 17 Nov 2022 | 17 Oct 2022 | 15 Dec 2022 | 0.19 Cash |
| 18 Aug 2022 | - | 15 Sep 2022 | 0.19 Cash |
| 19 May 2022 | 18 Apr 2022 | 15 Jun 2022 | 0.19 Cash |
| 17 Feb 2022 | 06 Jan 2022 | 15 Mar 2022 | 0.19 Cash |
| 18 Nov 2021 | 15 Oct 2021 | 15 Dec 2021 | 0.17 Cash |
| 19 Aug 2021 | 16 Jul 2021 | 15 Sep 2021 | 0.17 Cash |
| 19 May 2021 | 15 Apr 2021 | 15 Jun 2021 | 0.17 Cash |
| 18 Feb 2021 | 08 Jan 2021 | 15 Mar 2021 | 0.17 Cash |
| 19 Nov 2020 | 15 Oct 2020 | 15 Dec 2020 | 0.15 Cash |
| 14 Sep 2020 | 02 Sep 2020 | 30 Sep 2020 | 0.15 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 0.235 | 1 | 0.52 |
| 2025 | 0.880 | 4 | 2.28 |
| 2024 | 0.840 | 4 | 3.29 |
| 2023 | 0.800 | 4 | 2.85 |
| 2022 | 0.760 | 4 | 1.92 |
| 2021 | 0.680 | 4 | 1.71 |
| 2020 | 0.300 | 2 | 0.60 |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |